300705 九典制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)13.68820.88920.34021.11010.300
总资产报酬率 ROA (%)9.56914.24413.33514.2047.469
投入资产回报率 ROIC (%)11.23616.68915.44616.4498.478

边际利润分析
销售毛利率 (%)73.14177.15177.77678.50374.848
营业利润率 (%)23.29814.64712.52313.8759.377
息税前利润/营业总收入 (%)23.74315.16013.07114.7139.786
净利润/营业总收入 (%)20.79713.67711.59412.5488.410

收益指标分析
经营活动净收益/利润总额(%)86.73493.87397.37996.75692.283
价值变动净收益/利润总额(%)0.4760.5300.6351.2600.000
营业外收支净额/利润总额(%)-0.5151.937-0.3750.159-0.967

偿债能力分析
流动比率 (X)3.9873.4412.7152.7552.783
速动比率 (X)3.1432.8022.1732.1761.937
资产负债率 (%)28.98931.27432.48637.00926.093
带息债务/全部投入资本 (%)11.40012.59418.16023.693--
股东权益/带息债务 (%)727.037645.054430.872307.714867.393
股东权益/负债合计 (%)244.962219.758207.823170.203283.246
利息保障倍数 (X)42.04667.80421.97818.01519.621

营运能力分析
应收账款周转天数 (天)64.25367.10454.71145.6880.000
存货周转天数 (天)143.617148.212158.600189.1030.000